Capital One Initiates Coverage On Day One Biopharmaceutical with Overweight Rating, Announces Price Target of $40
Capital One analyst Naureen Quibria initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight rating and announces Price Target of $40.